Portfolio Lab

CG Oncology, Inc.

  • Stock
  • Ticker CGON
  • Nasdaq

Health care · Biotechnology · USA

$79.47 −2.97%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of CG Oncology, Inc. since 01/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CGONGlobal equities (VT)

$10,000 grew to $21,380. Global equities (VT): $14,390.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −67.5% in 04/2025, measured from the peak in 02/2024. It took 23 months to get back to the old peak.

1-year return
+95.2%
Return p.a. since 01/2024
+30.9%
Volatility p.a.
46.7%
Largest decline
−67.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue0.50.10.01.72.31.11.21.6
Gross profit–––0.1–––-1.1
Operating income-38-42-49-51-49-66-86-63
EBITDA-38-42-49-51-48-66-86-62
Net income-32-34-41-44-41-60-79-57
Earnings per share-0.48-0.45-0.54-0.57-0.51-0.71-0.90-0.64
Balance sheet
Total assets7557287017307921,1351,0861,047
Liabilities2123314239435756
Equity7337056706887531,0921,029991
Cash25741154532342028
Long-term debt0.0––3.03.03.03.03.0
Cash flow
Operating cash flow-21-29-28-39-36-57-46-48
Capital expenditure-0.20.00.0-0.10.0-0.3-0.5-1.1
Free cash flow-21-29-28-39-36-57-47-49

Value it:DCF calculatorMultiples calculator

Annual returns

* partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026−$0.64
6 Aug 2026−$0.90
8 May 2026−$0.71
27 Feb 2026−$0.51
14 Nov 2025−$0.57
8 Aug 2025−$0.54
13 May 2025−$0.45
28 Mar 2025−$0.48
12 Nov 2024−$0.30
8 Aug 2024−$3.93

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€6.4bn
Market cap in trading currency
$7.10bn
Enterprise value
$6.12bn
P/E
–
P/S
1,151.18
P/B
7.16
EV/Sales
992.01
EV/EBITDA
–
Earnings yield
–
FCF yield
-2.7%

Results (last four quarters)

Revenue
$6.17m
Gross profit
–
EBITDA
−$261m
Net income
−$237m
Earnings per share
−$2.76
Revenue per share
$0.07
Revenue growth
−3.7%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-4,293.5%
Net margin
-3,851.1%
Return on equity
-28.3%
Return on assets
-22.7%

Balance sheet and cash flow

Cash
$984m
Cash per share
$11.02
Financial debt
$3.00m
Debt/equity %
0
Current ratio
21.70
Book value per share
$11.09
Operating cash flow
−$187m
Free cash flow
−$189m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
89.3m
Volume
1.67m
Avg. volume 3 months
1.00m
Relative volume
1.4

Price and technicals

Price
$79.47
1 day
−3.0%
52-week high
$84.78
52-week low
$37.37
Distance to 52-week high
−6.3%
Distance to 52-week low
+112.7%
Distance to 50-day line
+15.4%
Distance to 200-day line
+17.9%
RSI (14)
60
Volatility 1M
88.0%

Performance

1 week
+6.8%
1 month
+27.1%
3 months
+1.6%
6 months
+23.7%
YTD
+91.4%
1 year
+86.5%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CGON performed since 01/2024?

$10,000 grew to $21,380 by 20 Nov 2026, which is +30.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CGON?

Volatility was 46.7% per year, measured on monthly returns. The largest decline from a peak was −67.5%, with the low in 04/2025.

How does CGON compare with a broad equity ETF?

Over the same period Global equities (VT) returned +13.8% per year at 12.3% volatility, CGON returned +30.9% at 46.7%. The correlation of monthly returns was 0.00; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

CG Oncology, Inc. (CGON): Return and risk | Portfolio Lab